Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition

Inhibitors of cyclin-dependent kinases CDK4 and CDK6 have been approved for treatment of hormone receptor–positive breast cancers. In contrast, triple-negative breast cancers (TNBCs) are resistant to CDK4/6 inhibition. Here, we demonstrate that a subset of TNBC critically requires CDK4/6 for prolife...

Descripción completa

Detalles Bibliográficos
Autores principales: Fassl, Anne, Brain, Christopher, Abu-Remaileh, Monther, Stukan, Iga, Butter, Deborah, Stepien, Piotr, Feit, Avery S., Bergholz, Johann, Michowski, Wojciech, Otto, Tobias, Sheng, Qing, Loo, Alice, Michael, Walter, Tiedt, Ralph, DeAngelis, Carmine, Schiff, Rachel, Jiang, Baishan, Jovanovic, Bojana, Nowak, Karolina, Ericsson, Maria, Cameron, Michael, Gray, Nathanael, Dillon, Deborah, Zhao, Jean J., Sabatini, David M., Jeselsohn, Rinath, Brown, Myles, Polyak, Kornelia, Sicinski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360435/
https://www.ncbi.nlm.nih.gov/pubmed/32704543
http://dx.doi.org/10.1126/sciadv.abb2210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360435/
https://www.ncbi.nlm.nih.gov/pubmed/32704543
http://dx.doi.org/10.1126/sciadv.abb2210

Ejemplares similares